TDRKH Antibody

What is TDRKH and why is it important in research?

TDRKH (also known as TDRD2) contains one Tudor domain and two KH domains, functioning primarily in germline development. It is highly expressed in testis and moderately in brain tissue . TDRKH participates in the primary piRNA biogenesis pathway by binding to Piwi proteins through its Tudor domain and is required for processing piRNA intermediates into mature piRNAs . Its role in transposable element suppression makes it essential for maintaining genomic integrity during reproduction . TDRKH is associated with pi-bodies and piP-bodies in germ cells, suggesting a role in transferring piRNA precursors or intermediates between these granules .

What applications are validated for TDRKH antibodies?

TDRKH antibodies have been validated for multiple applications:

Most antibodies show reactivity with human, mouse, and rat samples .

How is TDRKH protein expression distributed temporally and spatially?

Western blot analysis shows TDRKH (approximately 70 kDa) is highly expressed in testis and to a lesser extent in brain, with minimal expression in other tissues . Temporally, TDRKH shows low expression at postnatal day 7 (P7) but elevated expression by P14, P21, and in adult testes, correlating with meiosis onset .

Immunostaining reveals:

• At P1 and P7: Enriched in cytoplasm of spermatogonia in a granular pattern

• At P14: Strongly expressed in meiotic primary spermatocytes

• Adult tissue: High cytoplasmic expression in spermatocytes and round spermatids

TDRKH is not expressed in murine embryonic stem cells, and no specific signal is detected in Sertoli cells or interstitial Leydig cells, confirming germ cell-specific expression .

What are the optimal antigen retrieval methods for TDRKH IHC?

For paraffin-embedded sections, antigen retrieval is critical for detecting TDRKH. Two effective methods have been reported:

• TE buffer pH 9.0 (primary recommendation)

• Citrate buffer pH 6.0 (alternative method)

For frozen sections, brief fixation followed by permeabilization is typically sufficient. R&D Systems reports successful detection in frozen mouse testis sections using overnight incubation at 4°C . The specific localization to germ cells provides an internal positive control for optimization.

How should protein-protein interactions involving TDRKH be studied?

Multiple complementary approaches have been established:

• Co-immunoprecipitation:

  • TDRKH antibodies have successfully pulled down interaction partners including Miwi

  • The interaction with Miwi is RNA-independent (resistant to RNase A treatment)

  • IP followed by mass spectrometry can identify novel interactors

• Domain mapping:

  • The N-terminus of Miwi interacts with the Tudor domain of TDRKH

  • Point mutations in the Tudor domain (D390A, F391A) abolish binding to Miwi

  • Arginine to lysine mutations in PIWI proteins, especially in all three clusters of arginines, strongly attenuate interaction with TDRKH

• Methylation dependence:

  • Treatment with methyltransferase inhibitor MTA reduces the interaction between Miwi and TDRKH

  • This confirms that symmetric dimethylation of arginines mediates the interaction

What controls are essential when using TDRKH antibodies?

Proper experimental controls ensure reliable results:

• Tissue controls:

  • Positive: Testis tissue (high expression), brain tissue (moderate expression)

  • Negative: Other tissues with minimal expression

• Application-specific controls:

  • WB: Molecular weight marker (expected size: 67-70 kDa)

  • IP: IgG control and input control

  • IHC/IF: Secondary antibody-only control, counterstaining for context (e.g., DAPI)

• Specificity validation:

  • Peptide competition assay

  • TDRKH knockdown/knockout samples when available

  • Multiple antibodies targeting different epitopes

How can TDRKH antibodies be used to study piRNA biogenesis?

TDRKH antibodies enable multiple approaches to investigate piRNA biogenesis:

• Subcellular localization studies:

  • Co-immunofluorescence with markers for:

    • Pi-bodies (Mili, Tdrd1) - TDRKH shows partial co-localization

    • PiP-bodies (Miwi2, Mael) - TDRKH overlaps with cytoplasmic Miwi2

    • P-bodies (Ge-1, Ddx6) - TDRKH occasionally co-localizes with these markers

    • Mitochondrial markers (CoxIV) - TDRKH extensively co-localizes

• Protein complex analysis:

  • Immunoprecipitation with TDRKH antibodies followed by mass spectrometry has identified Miwi as a major interactor

  • RNase treatment can determine RNA-dependency of interactions

• Structural studies:

  • Crystal structure of the Tudor domain (PDB 3fdr) reveals the molecular basis for methylarginine recognition

  • The Tudor barrel is flanked by α-helices at both termini

What methodological approaches can identify TDRKH's role in transposon silencing?

TDRKH antibodies can help elucidate transposon silencing mechanisms:

• Expression correlation studies:

  • Immunofluorescence for TDRKH combined with in situ hybridization for transposon transcripts

  • Comparison of TDRKH expression with LINE-1 expression in mutant vs. wild-type contexts

• Developmental studies:

  • Tracking TDRKH expression during critical periods of transposon silencing using immunofluorescence

  • Co-localization with other transposon silencing factors

• Protein-protein interactions:

  • TDRKH antibodies can co-immunoprecipitate Miwi and Miwi2 , which are involved in transposon silencing

  • These interactions appear to be specific, as TDRKH does not strongly interact with Mili

What are the challenges in designing antibodies targeting specific TDRKH epitopes?

Generating epitope-specific antibodies for TDRKH presents several challenges:

• Domain-specific considerations:

  • The Tudor domain (aa 353-412) has structural similarity to other Tudor domains (e.g., Snd1)

  • KH domains (aa 52-115 and 124-190) share sequence homology with other RNA-binding proteins

• Isoform recognition:

  • Multiple splice variants exist with various deletions and substitutions

  • Some variants share a deletion of aa 562-606

  • Others show unique deletions of aa 108-152 and 76-79

• Rational design approaches:

  • Complementary peptide design methodologies can be applied to create antibodies targeting specific epitopes

  • This involves identifying peptides that bind with good specificity and affinity to target regions

  • Such peptides can be grafted onto antibody scaffolds to create highly specific antibodies

Why might TDRKH detection vary between tissues and developmental stages?

Several factors contribute to variation in TDRKH detection:

• Genuine biological differences:

  • Tissue-specific expression (high in testis, moderate in brain, low elsewhere)

  • Developmental regulation (low at P7, elevated at P14, P21, and adulthood)

  • Cell-type specific expression within tissues (spermatogonia, spermatocytes, round spermatids)

• Technical considerations:

  • Different optimal antibody dilutions for different tissues (1:500-1:10,000 for WB)

  • Varying fixation efficiencies and antigen retrieval requirements

  • Different subcellular localization patterns affecting accessibility

• Post-translational modifications:

  • Methylation-dependent interactions may affect epitope accessibility

  • Potential tissue-specific modifications

How can discrepancies in TDRKH molecular weight detection be resolved?

Variations in TDRKH molecular weight detection (typically 67-72 kDa) may result from:

• Technical variables:

  • Different gel systems and running conditions

  • Varying protein ladder calibration

  • Sample preparation methods (denaturing conditions, buffer composition)

• Biological variables:

  • Post-translational modifications affecting mobility

  • Species differences (human vs. mouse TDRKH)

  • Splice variants with varying molecular weights

• Antibody-specific factors:

  • Epitope location affecting detection of specific isoforms

  • Cross-reactivity profiles

To resolve discrepancies, researchers should:

• Specify gel system and conditions

• Include detailed methods for sample preparation

• Use multiple antibodies targeting different epitopes

• Consider species-specific and isoform-specific detection

What approaches can minimize non-specific binding in TDRKH immunodetection?

To optimize signal-to-noise ratio:

• Antibody dilution optimization:

  • Perform titration experiments across recommended ranges

  • WB: 1:2000-1:10,000

  • IHC: 1:50-1:500

  • IF: 1:50-1:500

• Buffer optimization:

  • Include 0.05-0.1% Tween-20 in washing buffers

  • Use PBS with 0.02% sodium azide and 50% glycerol pH 7.3 for storage

• Blocking optimization:

  • 5% normal serum or BSA

  • Extended blocking times (1-2 hours)

• Antigen retrieval refinement:

  • Compare TE buffer pH 9.0 and citrate buffer pH 6.0

  • Optimize temperature and duration

• Validation approaches:

  • Peptide competition assays

  • Testing in tissues with known negative expression

How can new antibody design technologies enhance TDRKH research?

Rational antibody design methods offer promising opportunities for TDRKH research:

• Complementary peptide design:

  • Identifying peptides that bind with specificity to target TDRKH epitopes

  • These peptides can be grafted onto antibody scaffolds

  • This approach could target specific domains (Tudor, KH) or isoforms

• Domain-specific antibodies:

  • Designing antibodies specifically targeting the Tudor domain to study methylarginine recognition

  • KH domain-specific antibodies to investigate RNA-binding capabilities

• Integration with proximity labeling:

  • Fusion of TDRKH antibody fragments with proximity labeling enzymes

  • This could identify transient interaction partners in specific cellular compartments

What methodological advances could improve investigation of TDRKH function?

Several technical advances could enhance TDRKH research:

• Single-cell approaches:

  • Single-cell immunofluorescence combined with RNA-seq

  • This would enable correlation of TDRKH expression with transcriptome changes

• Live-cell imaging:

  • Development of nanobodies or intrabodies against TDRKH

  • These could track TDRKH dynamics in living cells during spermatogenesis

• Cryo-EM studies:

  • Structural characterization of TDRKH-containing complexes

  • This would provide insight into how TDRKH functions within larger molecular assemblies

• Targeted degradation approaches:

  • PROTAC or degron technologies targeting TDRKH

  • These could allow temporal control of TDRKH depletion to study acute effects